Insights

As clinical trials become more diverse, patient heterogeneity, placebo responses, and inter-site variability become more pronounced, contributing to high rates of failed trials and extended development timelines and costs. It is time for the biopharmaceutical industry to reconsider its approaches. Most of the “unsolvable” challenges within the medical community – especially within clinical research –

Earlier this month, the IASP (International Association for the Study of Pain) meeting marked a significant moment in honoring the vision of Professor John Bonica founder of IASP. In 1973, Professor Bonica successfully convened a group of experts in Issaquah, Washington, to chart a path forward for improving the lives of patients suffering from pain.

The 2024 International Osteoarthritis Research Society (OARSI) conference concluded last week, offering valuable exchange and information. What insights could we gather from these dynamic four days? One of the most interesting themes was the relationship between patients’ osteoarthritis (OA), pain, and psychosocial state – a crucial but often overlooked topic. Indeed, OA studies typically assess

For high quality clinical trial data, the voice of the participant (i.e. patient and/or caregiver) must be captured in the language that they can understand. In this blog post, we discuss the linguistic validation process of the participant questionnaire behind Cognivia’s clinical trial technology.

There are multiple techniques to account for these expectations in studies, including site stafftraining, subject training before the start of the study, and applying  an adjustment covariate.